Olema Pharmaceuticals, Inc. (OLMA) FY2025 10-K Annual Report
Olema Pharmaceuticals, Inc. (OLMA) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 16, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Olema Pharmaceuticals, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Clinical-stage biopharma developing next-generation targeted therapies for ER+ breast cancer, emphasizing oral small molecule endocrine therapies
- • New emphasis: Initiated pivotal Phase 3 OPERA-01 trial for palazestrant monotherapy (2023) and Phase 3 OPERA-02 trial with ribociclib combination (2025)
- • Strategic shift: Collaboration with Novartis for ribociclib supply, advancing palazestrant as potential endocrine therapy of choice in frontline metastatic breast cancer
- • Quantitative highlight: Over 400 patients treated with palazestrant; FDA Fast Track designation granted in July 2022
- • Noteworthy: Second product OP-3136 entered clinical development in late 2024 targeting KAT6, with IND clearance and ongoing Phase 1 trial enrollment
Management Discussion & Analysis
- • Revenue and profitability details not disclosed in the provided MD&A excerpt
- • No segment performance data available in the provided text
- • Cash flow, capital allocation, buybacks, dividends, and capex information not included
- • Forward-looking statements indicating potential risks and uncertainties affecting actual results and events timing
Risk Factors
- • FDA regulatory risk: reliance on successful OPERA-01 Phase 3 trial results expected fall 2026 for NDA submission and potential FDA approval by late 2027
- • Geopolitical/macroeconomic threat: funding and operational risks tied to global economic uncertainty and volatile credit markets impacting capital raises and collaborations
- • Supply chain vulnerability: dependence on third-party contract manufacturers (CMOs) for clinical and potential commercial production with no in-house manufacturing
- • Competitive risk: Novartis collaboration supplying ribociclib for OPERA-02 trial, with palazestrant competing against established CDK4/6 inhibitors like palbociclib and ribociclib
- • Financial risk: accumulated deficit $597.6 million with net losses increasing to $162.5 million in 2025, requiring ongoing substantial capital raises including $237 million net from 2024 private placement
Olema Pharmaceuticals, Inc. FY2025 Key Financial MetricsXBRL
Net Income
-$162M
▼ -25.5% YoY
ROE
-33.9%
▼ -229bp YoY
Total Assets
$533M
▲ +18.3% YoY
EPS (Diluted)
$-1.87
▲ +15.0% YoY
Operating Cash Flow
-$147M
▼ -40.6% YoY
Source: XBRL data from Olema Pharmaceuticals, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Olema Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.